ValiRx (LON:VAL) Sets New 1-Year Low – Time to Sell?

ValiRx plc (LON:VAL) reached a new 52-week low during trading on Monday . The company traded as low as GBX 0.71 ($0.01) and last traded at GBX 0.72 ($0.01), with a volume of 2828047 shares trading hands. The stock had previously closed at GBX 0.75 ($0.01).

ValiRx Trading Up 1.4 %

The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The company has a market cap of £972,772.50, a price-to-earnings ratio of -35.50 and a beta of 0.59. The firm has a 50 day moving average price of GBX 1.46 and a two-hundred day moving average price of GBX 2.05.

ValiRx Company Profile

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.